References:
1. Sarkar K, Han SS, Wen KK, et al. R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome.J Allergy Clin Immunol . 2018;142(1). doi:10.1016/j.jaci.2017.11.0232. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options. Blood . 2010;115(16). doi:10.1182/blood-2009-09-2390873. Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich Syndrome: Diagnosis, Clinical and Laboratory Manifestations, and Treatment. Biol Blood Marrow Transplant . 2009;15(1 SUPPL.). doi:10.1016/j.bbmt.2008.10.0074. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol . 2006;117(4):725-738. doi:10.1016/j.jaci.2006.02.0055. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review.Ann N Y Acad Sci . 2013;1285(1):26-43. doi:https://doi.org/10.1111/nyas.120496. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. J Clin Immunol . 2018;38(1):13-27. doi:10.1007/s10875-017-0453-z7. Rivers E, Worth A, Thrasher AJ, Burns SO. Bleeding and splenectomy in Wiskott-Aldrich syndrome: A single-centre experience. J Allergy Clin Immunol Pract . 2019;7(3):1042-1044.e1. doi:10.1016/j.jaip.2018.07.0098. Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.Ther Adv Hematol . 2012;3(3):155-164. doi:10.1177/20406207124425259. Merli P, Strocchio L, Vinti L, Palumbo G, Locatelli F. Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother . 2015;16(14). doi:10.1517/14656566.2015.108551210. Gerrits AJ, Leven EA, Frelinger AL, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood . 2015;126(11). doi:10.1182/blood-2014-09-60257311. Abdelmoumen K, Fabre M, Ducastelle-Lepretre S, et al. Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia. Acta Haematol . 2021;144(3). doi:10.1159/00050992212. Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv . 2018;2(4). doi:10.1182/bloodadvances.201701066013. Rivers E, Worth A, Thrasher AJ, Burns SO. How I manage patients with Wiskott Aldrich syndrome. Br J Haematol . 2019;185(4):647-655. doi:10.1111/bjh.1583114. Khoreva A, Abramova I, Deripapa E, et al. Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. Br J Haematol . 2021;192(2):366-374. doi:10.1111/bjh.1717415. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost JTH . 2010;8(9):2063-2065. doi:10.1111/j.1538-7836.2010.03975.x16. Gabelli M, Marzollo A, Notarangelo LD, Basso G, Putti MC. Eltrombopag use in a patient with Wiskott–Aldrich syndrome. Pediatr Blood Cancer . 2017;64(12). doi:10.1002/pbc.2669217. Moriyama M, Nishikawa T, Nakamura T, et al. [Improvement in platelet count and bleeding symptom during treatment with eltrombopag in a patient with X-linked thrombocytopenia].Rinsho Ketsueki . 2021;62(4).18. Waleed Ghanima, Nichola Cooper, Francesco Rodeghiero, Bertrand Godeau, James B. Bussel. Thrombopoietin receptor agonists: ten years later. Haematologica . 2019;104(6):1112-1123. doi:10.3324/haematol.2018.21284519. van Dijk WEM, Brandwijk ON, Heitink-Polle KMJ, Schutgens REG, van Galen KPM, Urbanus RT. Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. Blood Rev . 2021;47:100774. doi:10.1016/j.blre.2020.10077420. Chiou T-J, Chang Y-F, Wang M-C, et al. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. Transl Res . 2015;166(6):750-761.e4. doi:10.1016/j.trsl.2015.09.005